{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:34:36Z","timestamp":1762324476686},"reference-count":57,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The growing body of genomic information collected and applied to mature aggressive B-cell lymphoma diagnosis and management has exploded over the last few years due to improved technologies with high-throughput capacity, suitable for use on routine formalin-fixed, paraffin-embedded tissue biopsies, and decreasing costs. These techniques have made evaluation of complete DNA sequences, RNA-expression patterns, translocations, copy-number alterations, loss of heterozygosity, and DNA-methylation patterns possible on a genome-wide level. This chapter will present a case of aggressive B-cell lymphoma and discuss the most important genomic abnormalities that characterize this group of entities in the recent update to the fourth edition of the World Health Organization (WHO) lymphoma classification system. Genomic abnormalities discussed will include those necessary for certain diagnoses such as translocations of MYC, BCL2, or BCL6; gene-expression-profiling categorization; the newly defined Burkitt-like lymphoma with 11q abnormalities; prognostic and predictive mutations, as well as tumor heterogeneity. Finally, our current practices for clinical triage of specimens with a potential diagnosis of aggressive B-cell lymphomas are also described. Options for treatment at relapse, in light of these genomic features, will be discussed in the third presentation from this session.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.69","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"69-74","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Genomics of aggressive B-cell lymphoma"],"prefix":"10.1182","volume":"2018","author":[{"given":"Allison","family":"Rosenthal","sequence":"first","affiliation":[{"name":"Division of Hematology Medical Oncology, Division of Internal Medicine, Mayo Clinic Arizona, Phoenix, AZ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"18","key":"2019111523450435400_B1","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019111523450435400_B2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111523450435400_B3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/his.12178","article-title":"MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection","volume":"63","author":"Mu\u00f1oz-M\u00e1rmol","year":"2013","journal-title":"Histopathology"},{"issue":"22","key":"2019111523450435400_B4","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2019111523450435400_B5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111523450435400_B6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2019111523450435400_B7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":"B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"issue":"21","key":"2019111523450435400_B8","doi-asserted-by":"crossref","first-page":"18374","DOI":"10.18632\/oncotarget.4073","article-title":"MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"2019111523450435400_B9","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"22","key":"2019111523450435400_B10","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group","volume":"35","author":"Staiger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"2019111523450435400_B11","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111523450435400_B12","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111523450435400_B13","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","article-title":"Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact","volume":"129","author":"Ennishi","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111523450435400_B14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"6769","key":"2019111523450435400_B15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"17","key":"2019111523450435400_B16","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"2019111523450435400_B17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111523450435400_B18","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111523450435400_B19","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","article-title":"Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction","volume":"106","author":"Bea","year":"2005","journal-title":"Blood"},{"issue":"13","key":"2019111523450435400_B20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"issue":"16","key":"2019111523450435400_B21","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111523450435400_B22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/modpathol.2010.76","article-title":"Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas","volume":"23","author":"Seegmiller","year":"2010","journal-title":"Mod Pathol"},{"issue":"8","key":"2019111523450435400_B23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","article-title":"A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma","volume":"123","author":"Salaverria","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111523450435400_B24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ajcp\/aqx139","article-title":"The 11q-gain\/loss aberration occurs recurrently in MYC-negative Burkitt-like lymphoma with 11q aberration, as well as MYC-positive Burkitt lymphoma and MYC-positive high-grade B-cell lymphoma, NOS","volume":"149","author":"Grygalewicz","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2019111523450435400_B25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/path.2410","article-title":"MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation","volume":"216","author":"Leucci","year":"2008","journal-title":"J Pathol"},{"issue":"7457","key":"2019111523450435400_B26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"3","key":"2019111523450435400_B27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2017.251","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"32","author":"Karube","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2019111523450435400_B28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"7","key":"2019111523450435400_B29","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111523450435400_B30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"issue":"2","key":"2019111523450435400_B31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin Hematol"},{"issue":"10","key":"2019111523450435400_B32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"2019111523450435400_B33","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"7277","key":"2019111523450435400_B34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"5870","key":"2019111523450435400_B35","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"7332","key":"2019111523450435400_B36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"6","key":"2019111523450435400_B37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","article-title":"BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma","volume":"18","author":"Mandelbaum","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111523450435400_B38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ccr.2010.11.024","article-title":"Constitutive canonical NF-\u03baB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma","volume":"18","author":"Calado","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111523450435400_B39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.20052204","article-title":"Inactivation of the PRDM1\/BLIMP1 gene in diffuse large B cell lymphoma","volume":"203","author":"Pasqualucci","year":"2006","journal-title":"J Exp Med"},{"issue":"3","key":"2019111523450435400_B40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111523450435400_B41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"30","key":"2019111523450435400_B42","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2019111523450435400_B43","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111523450435400_B44","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0840","article-title":"EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL","volume":"16","author":"Brach","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"52","key":"2019111523450435400_B45","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"29","key":"2019111523450435400_B46","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1038\/onc.2015.442","article-title":"Inactivating mutations in GNA13 and RHOA in Burkitt\u2019s lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the G\u03b113\/RhoA axis in B cells","volume":"35","author":"O\u2019Hayre","year":"2016","journal-title":"Oncogene"},{"issue":"7530","key":"2019111523450435400_B47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature13765","article-title":"Loss of signalling via G\u03b113 in germinal centre B-cell-derived lymphoma","volume":"516","author":"Muppidi","year":"2014","journal-title":"Nature"},{"issue":"5","key":"2019111523450435400_B48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published corrections, published online ahead of print 28 June 2018, appear in Nat Med. doi:10.1038\/s41591-018-0097-4 and Nat Med. doi:10.1038\/s41591-018-0098-3]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"2019111523450435400_B49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"7467","key":"2019111523450435400_B50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"issue":"19","key":"2019111523450435400_B51","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor heterogeneity: evolution through space and time","volume":"72","author":"Swanton","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"2019111523450435400_B52","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111523450435400_B53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12439","article-title":"Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma","volume":"163","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111523450435400_B54","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"364","key":"2019111523450435400_B55","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"7","key":"2019111523450435400_B56","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.3324\/haematol.2015.123612","article-title":"Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis","volume":"100","author":"Bohers","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2019111523450435400_B57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/69\/1251604\/hem01809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/69\/1251604\/hem01809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T05:28:51Z","timestamp":1573882131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/69\/277564\/Genomics-of-aggressive-Bcell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.69","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}